Analysts’ Recent Ratings Changes for Forte Biosciences (FBRX)

Several analysts have recently updated their ratings and price targets for Forte Biosciences (NASDAQ: FBRX):

• 7/28/2026 – Forte Biosciences was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 7/28/2026 – Forte Biosciences was downgraded by Barclays PLC from “overweight” to “equal weight”. They now have a $77.00 price target on the stock, up from $74.00.
• 7/27/2026 – Forte Biosciences was given a new $77.00 price target by Evercore Inc.
• 7/27/2026 – Forte Biosciences was downgraded by TD Cowen from “strong-buy” to “hold”.
• 7/27/2026 – Forte Biosciences was downgraded by Evercore Inc from “strong-buy” to “hold”.
• 7/27/2026 – Forte Biosciences was downgraded by Brookline Capital Markets from “strong-buy” to “hold”.
• 7/25/2026 – Forte Biosciences was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 7/21/2026 – Forte Biosciences is now covered by Barclays PLC. They set an “overweight” rating and a $74.00 price target on the stock.
• 7/21/2026 – Forte Biosciences is now covered by Barclays PLC. They set an “overweight” rating and a $74.00 price target on the stock.
• 7/12/2026 – Forte Biosciences was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 7/8/2026 – Forte Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.